利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

8 条记录 (耗时 0.026 秒)

    Antibodies to motilin homologs
    1.
    发明申请
    Antibodies to motilin homologs 审中-公开
    胃动素同系物的抗体

    公开(公告)号：US20050106146A1

    公开(公告)日：2005-05-19

    申请号：US10927484

    申请日：2004-08-25

    申请人： Paul Sheppard ,  Theresa Deisher ,  Paul Bishop ,  Stephen Jaspers ,  Virender Labroo

    发明人： Paul Sheppard ,  Theresa Deisher ,  Paul Bishop ,  Stephen Jaspers ,  Virender Labroo

    IPC分类号： A61K38/00 ,  C07K14/575 ,  A61K39/395 ,  C07K16/26

    CPC分类号： C07K14/575 ,  A61K38/00

    摘要： The present invention is directed to polynucleotides, polypeptides and peptide fragments thereof, and uses thereof for a novel cDNA sequence which has homology to motilin. Tissue distribution of the mRNA for the novel polypeptide is specific to the stomach, small intestine and pancreas. The present invention further includes agonists, antagonists, antibodies, host cells expressing the cDNA encoding the novel motilin homologs and methods for increasing gastric motility using the novel molecules.

    摘要翻译： 本发明涉及多核苷酸，多肽及其肽片段及其与胃动素同源性的新cDNA序列的用途。 新型多肽的mRNA的组织分布特异于胃，小肠和胰腺。 本发明还包括激动剂，拮抗剂，抗体，表达编码新型胃动素同系物的cDNA的宿主细胞和使用新分子增加胃动力的方法。

    Isoprenoid pathway inhibitors for stimulating cartilage growth
    2.
    发明申请
    Isoprenoid pathway inhibitors for stimulating cartilage growth 审中-公开
    用于刺激软骨生长的异戊二醛途径抑制剂

    公开(公告)号：US20050272801A1

    公开(公告)日：2005-12-08

    申请号：US11167054

    申请日：2005-06-24

    申请人： Shirley Gasper ,  Robert West ,  Theresa Martinez ,  Kirk Robbins ,  Patricia McKernan ,  Nand Baindur ,  Virender Labroo ,  Gregory Mundy

    发明人： Shirley Gasper ,  Robert West ,  Theresa Martinez ,  Kirk Robbins ,  Patricia McKernan ,  Nand Baindur ,  Virender Labroo ,  Gregory Mundy

    IPC分类号： A23L1/30 ,  A61K31/00 ,  A61K31/192 ,  A61K31/22 ,  A61K31/225 ,  A61K31/366 ,  A61K31/40 ,  A61K31/404 ,  A61K31/405 ,  A61K31/4409 ,  A61K31/47 ,  A61K31/505 ,  A61K45/06 ,  A61P1/02 ,  A61P3/14 ,  A61P5/20 ,  A61P19/08 ,  A61P19/10 ,  C07D207/416 ,  C07D213/54 ,  C07D215/14

    CPC分类号： C07D215/14 ,  A23L33/10 ,  A61K31/00 ,  A61K31/192 ,  A61K31/22 ,  A61K31/225 ,  A61K31/366 ,  A61K31/40 ,  A61K31/404 ,  A61K31/405 ,  A61K31/505 ,  A61K45/06 ,  A61K2300/00

    摘要： Compounds of the formula wherein X in each of formulas (1) and (2) represents a substituted or unsubstituted alkylene, alkenylene, or alkynylene linker of 2-6C; Y is of the formula or a stereoisomer thereof, wherein R1 is substituted or unsubstituted alkyl; each R2 is independently H, hydroxy, alkoxy (1-6C) or lower alkyl (1-4C); R3 is H, hydroxy, or alkoxy (1-6C); or Y is of the formula wherein each n is 1, Z is N, K comprises a substituted or unsubstituted aromatic carbocyclic or heterocyclic ring system which may optionally be spaced from the linkage position shown in formula (7) by a linker of 1-2C, or in formula (7), Z may be spaced from the carbon bonded to X by ═CR6— wherein R6 is H or linear, branded or cyclic alkyl (1-6C), R5 is H or linear, branched or cyclic alkyl, and R′ represents a cation, H or a substituted or unsubstituted alkyl group of 1-6C, promote bone formation and are thus useful in treating osteoporosis, bone fracture or deficiency, primary or secondary hyperparathyroidism, periodontal disease or defect, metastatic bone disease, osteolytic bone disease, post-plastic surgery, post-prosthetic joint surgery, and post-dental implantation. Also disclosed is a method to identify additional compounds which are inhibitors of enzymes in the isoprenoid scheme especially of HMG-CoA reductase which results in prenylation of proteins and in the synthesis of steroids or of inhibitors of their production which are useful in treating bone disorders.

    摘要翻译： 式（1）和（2）中的X表示取代或未取代的2-6C的亚烷基，亚烯基或亚炔基接头; Y是下式或其立体异构体，其中R 1是取代或未取代的烷基; 每个R 2独立地是H，羟基，烷氧基（1-6C）或低级烷基（1-4C）; R 3是H，羟基或烷氧基（1-6C）; 或Y具有下式：其中每个n是1，Z是N，K包括取代或未取代的芳族碳环或杂环系统，其可以任选地与式（7）所示的连接位置间隔1-2- ，或式（7）中，Z可以与通过-CR 6键合到X的碳隔开，其中R 6是H或直链的，有品牌的或环状的烷基（ 1-6C）中，R 5是H或直链，支链或环状的烷基，R'表示阳离子，H或1-6C的取代或未取代的烷基，促进骨形成，因此 可用于治疗骨质疏松症，骨折或缺陷，原发性或继发性甲状旁腺功能亢进，牙周病或缺损，转移性骨病，溶骨性骨病，整形外手术，假体后关节手术和牙后植入术。 还公开了一种鉴定另外的化合物的方法，该化合物是类异戊二烯方案中尤其是HMG-CoA还原酶中的酶的抑制剂，其导致蛋白质的异戊烯化，以及合成类固醇或其生产抑制剂，其可用于治疗骨骼疾病。

    Transglutaminase cross-linkable polypeptides and methods relating thereto
    6.
    发明授权
    Transglutaminase cross-linkable polypeptides and methods relating thereto 失效
    转谷氨酰胺酶可交联多肽及其相关方法

    公开(公告)号：US5939385A

    公开(公告)日：1999-08-17

    申请号：US483236

    申请日：1995-06-07

    申请人： Virender Labroo ,  Sharon J. Busby

    发明人： Virender Labroo ,  Sharon J. Busby

    IPC分类号： A61L24/10 ,  C07K14/47 ,  C07K14/75 ,  A61K38/00

    CPC分类号： C07K14/75 ,  A61L24/106 ,  C07K14/4732

    摘要： Polypeptides of from about 9-120 amino acid residues comprising a truncated segment of fibrinogen which may be flanked by elastomeric peptides, wherein the polypeptides are cross-linkable by a transglutaminase, homo- and copolymers containing such polypeptides are disclosed. The homo- and co-polymers disclosed herein are useful in tissue sealant and wound healing formulations.

    摘要翻译： 包含约9-120个氨基酸残基的多肽，其包含纤维蛋白原的截短区段，其可以侧翼为弹性肽，其中所述多肽可通过转谷氨酰胺酶交联，包含此类多肽的均聚物和共聚物。 本文公开的均聚物和共聚物可用于组织密封剂和伤口愈合制剂。

    Glucagon antagonists and methods relating thereto
    7.
    发明授权
    Glucagon antagonists and methods relating thereto 失效
    胰高血糖素拮抗剂及其相关方法

    公开(公告)号：US5508304A

    公开(公告)日：1996-04-16

    申请号：US288875

    申请日：1994-08-10

    申请人： Robert R. West ,  Virender Labroo ,  James R. Piggott ,  Robert A. Smith ,  Patricia A. McKernan

    发明人： Robert R. West ,  Virender Labroo ,  James R. Piggott ,  Robert A. Smith ,  Patricia A. McKernan

    IPC分类号： A61K31/12 ,  A61K31/122 ,  A61K31/22 ,  A61K31/27 ,  C12P15/00 ,  A61K31/21

    CPC分类号： A61K31/122 ,  A61K31/12 ,  A61K31/22 ,  A61K31/27 ,  C12P15/00

    摘要： Glucagon antagonists and methods relating thereto are disclosed. The glucagon antagonists include skyrin and skyrin analogs, and serve to inhibit the stimulation of a glucagon-induced response pathway, such as the adenylate cyclase response pathway or the inositol phosphate response pathway. The glucagon antagonists may be used within therapeutic compositions to treat disease states associate with elevated glucose levels, including diabetes and hyperglycemia. The present invention also discloses a biologically pure culture of ATCC accession number 74200, as well as methods relating to the production of glucagon antagonists by cultivating the same in a nutrient medium and recovering the glucagon antagonist therefrom.

    摘要翻译： 公开了胰高血糖素拮抗剂及其相关方法。 胰高血糖素拮抗剂包括天冬氨酸和天冬氨酸类似物，并且用于抑制胰高血糖素诱导的应答途径的刺激，例如腺苷酸环化酶应答途径或肌醇磷酸应答途径。 胰高血糖素拮抗剂可用于治疗组合物内以治疗与升高的葡萄糖水平相关的疾病状态，包括糖尿病和高血糖。 本发明还公开了ATCC保藏号74200的生物纯纯培养物，以及通过在营养培养基中培养并从其中回收胰高血糖素拮抗剂来产生胰高血糖素拮抗剂的方法。